出血后急性呼吸窘迫综合征发生的危险因素
该研究为PROPPR试验的二次分析,纳入12个北美I级创伤中心中预测需大量输血的损伤患者,随机接受血浆:血小板:红细胞1:1:1或1:1:2比例输注。共分析454例(1:1:1组230例,1:1:2组224例),两组ARDS发生率(14.8% vs. 18.4%)、无 ventilator 天数(24 vs. 24)、无ICU天数(17.5 vs. 18)、住院时长(22天 vs. 18天)及30天死亡率(28% vs. 28%)均无显著差异。ARDS与钝性损伤(OR 3.61 [1.53-8.81] P<0.01)及胸部AIS评分增加(OR 1.40 [1.15-1.71] P<0.01)相关;0至6小时每输注500 mL晶体液与ARDS发生率增加9%相关(OR 1.09 [1.04-1.14] P<0.01),而0至6小时或7至24小时输注血液制品非肺损伤危险因素。
要点
- 在预测需大量输血的损伤患者中,0至6小时每输注500 mL晶体液,ARDS发生率增加9%(OR 1.09 [1.04-1.14] P<0.01)。
- 钝性损伤与ARDS风险升高相关(OR 3.61 [1.53-8.81] P<0.01),胸部AIS评分每增加1分,ARDS风险升高(OR 1.40 [1.15-1.71] P<0.01)。
- 血浆:血小板:红细胞1:1:1与1:1:2两组ARDS发生率无显著差异(14.8% vs. 18.4%)。
- 0至6小时或7至24小时输注血液制品不是肺损伤的危险因素。
- 急性晶体液暴露是出血后预防ARDS的潜在可干预危险因素。
适用人群与场景
- PROPPR研究纳入的预测需大量输血的损伤患者,来自12个北美I级创伤中心。
- 本二次分析纳入标准:生存超过24小时、入住ICU且有记录的PaO2/FiO2(P/F)比值。
诊断标准与关键阈值
- ARDS定义:P/F比值<200,伴双肺浸润,由研究者裁定。
研究设计与关键结果
- 研究类型:PROPPR研究的二次分析;样本量454例(1:1:1组230例,1:1:2组224例);12个北美I级创伤中心;人群为预测需大量输血的损伤患者;干预为血浆:血小板:红细胞1:1:1 vs. 1:1:2比例输注。
- 主要终点结果:两组ARDS发生率无显著差异(1:1:1组14.8% vs. 1:1:2组18.4%)。
- 关键次要终点:无 ventilator 天数(24 vs. 24)、无ICU天数(17.5 vs. 18)、住院时长(22天 vs. 18天)、30天死亡率(28% vs. 28%)均无显著差异。
- ARDS危险因素:钝性损伤(OR 3.61 [1.53-8.81] P<0.01)、胸部AIS评分增加(OR 1.40 [1.15-1.71] P<0.01)、0至6小时每500 mL晶体液(OR 1.09 [1.04-1.14] P<0.01)。
- 血液制品在0至6小时或7至24小时输注均不是肺损伤的危险因素。
证据类型、等级与局限
- 证据类型:随机对照试验(PROPPR)的二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为急性晶体液暴露是出血后预防ARDS的潜在可干预危险因素。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) study evaluated the effects of plasma and platelets on hemostasis and mortality after hemorrhage. The pulmonary consequences of resuscitation strategies that mimic whole blood, remain unknown.
METHODS: A secondary analysis of the PROPPR study was performed. Injured patients predicted to receive a massive transfusion were randomized to 1:1:1 versus 1:1:2 plasma-platelet-red blood cell ratios at 12 Level I North American trauma centers. Patients with survival >24 h, an intensive care unit (ICU) stay, and a recorded PaO2/FiO2 (P/F) ratio were included. Acute respiratory distress syndrome (ARDS) was defined as a P/F ratio < 200, with bilateral pulmonary infiltrates, and adjudicated by investigators.
RESULTS: Four hundred fifty-four patients were reviewed (230 received 1:1:1, 224 1:1:2). Age, sex, injury mechanism, and regional abbreviated injury scale (AIS) scores did not differ between cohorts. Tidal volume, positive end-expiratory pressure, and lowest P/F ratio did not differ. No significant differences in ARDS rates (14.8% vs. 18.4%), ventilator-free (24 vs. 24) or ICU-free days (17.5 vs. 18), hospital length of stay (22 days vs. 18 days), or 30-day mortality were found (28% vs. 28%). ARDS was associated with blunt injury (OR 3.61 [1.53-8.81] P < 0.01) and increasing chest AIS (OR 1.40 [1.15-1.71] P < 0.01). Each 500 mL of crystalloid infused during hours 0 to 6 was associated with a 9% increase in the rate of ARDS (OR 1.09 [1.04-1.14] P < 0.01). Blood given at 0 to 6 or 7 to 24 h were not risk factors for lung injury.
CONCLUSION: Acute crystalloid exposure, but not blood products, is a potentially modifiable risk factor for the prevention of ARDS following hemorrhage.
参考来源
- Robinson BRH, Cohen MJ, Holcomb JB, et al. Risk Factors for the Development of Acute Respiratory Distress Syndrome Following Hemorrhage. Shock. 2018. PMID: 29194339. doi:10.1097/SHK.0000000000001073
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。